Cases & Deals

NGM Biopharmaceuticals completes $107 million IPO

Clients NGM Biopharmaceuticals, Inc.

Jones Day served as IP counsel in connection with the $107 million initial public offering of NGM Biopharmaceuticals, Inc. (NASDAQ: NGM). NGM is a clinical stage biopharmaceutical company focused on developing novel therapeutics based on scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.